Table 1

Patient clinicopathological and dose-response characteristics

PatientAge (yr)SexPrimary diagnosisSitePrior chemotherapyDose of doxorubicin delivered via ILP (mg/m2)Clinical response
130FSynovial cell sarcomaThighMAIDa40Progression of disease
246FUterine leiomyosarcomaUterusDoxorubicin and DTIC40Progression of disease
329FClear cell sarcomaParaspinalNone40Progression of disease
426FAlveolar soft part sarcomaThighMAID40Progression of disease
544MMalignant fibrous histiocytomaThighMAID80Progression of disease
  • a MAID, Mesna, Adriamycin, ifosfamide, and DTIC (dacarbazine).